Printer Friendly

CYTOGEN AND CYTORAD PROSTATE CANCER IMAGING AGENT ENTERS PHASE III OF HUMAN TESTING

 CYTOGEN AND CYTORAD PROSTATE CANCER IMAGING AGENT
 ENTERS PHASE III OF HUMAN TESTING
 PRINCETON, N.J., June 3 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) and Cytorad Incorporated (NASDAQ: CYTDZ) reported today that, based on the encouraging results of the Phase I and Phase II human clinical trials for OncoScint(R) prostate, Phase III trials to evaluate pre-surgical patients have been initiated.
 The study will take place at approximately 20 U.S. institutions, including leading comprehensive cancer centers. OncoScint prostate is a monoclonal antibody-based imaging agent which is expected to be useful in determining the extent and location of prostate cancer.
 Positive findings from Phase II studies included the detection of pelvic lymph node metastases, the detection of occult disease (negative CT), and the product correctly confirmed the absence of prostate cancer. No patients experienced serious side effects and only one patient developed a detectable level of human anti-mouse antibody (HAMA). In commenting on these results, Thomas J. McKearn, M.D., Ph.D., Cytogen's president, said, "OncoScint prostate has the potential to differentiate those patients in whom prostate surgery would be indicated from those in whom prostate surgery would not have any chance for cure."
 The American Cancer Society states that prostate cancer is the most common cancer in men; approximately one of every 11 men will develop this disease in their lifetime. In 1992, an estimated 132,000 new cases of prostate cancer will occur in the United States and nearly 34,000 will die from the disease.
 Cytogen is a biopharmaceutical company engaged in the development of proprietary systems utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances in human health care applications. Cytogen uses its patented and proprietary antibody "linker" technology to develop specific cancer diagnostic imaging and cancer therapeutic products, as well as certain other products.
 Cytorad is a newly formed company which, through Cytogen, will engage in the research and development of proprietary antibody-based delivery systems for diagnosis and treatment of prostate and bladder cancers.
 /delval/
 -0- 6/3/92
 /CONTACT: Martin D. Cleary, group vice president of Cytogen, 609-987-8221/
 (CYTO CYTD) CO: Cytogen Corporation; Cytorad Incorporated ST: New Jersey IN: MTC SU:


JS -- PH010 -- 6541 06/03/92 10:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1992
Words:368
Previous Article:KASH N' KARRY THIRD QUARTER BRINGS FIRST PROFIT; RECORD CASH FLOW
Next Article:NUTRASWEET(R) SPOONFUL(TM) SOON TO BE ON TABLES ACROSS THE COUNTRY
Topics:


Related Articles
CYTOGEN AND CYTORAD ANNOUNCE UNIT OFFERING
CYTOGEN CORPORATION ANNOUNCES STRONG SECOND QUARTER RESULTS
CYTOGEN ANNOUNCES SATISFACTION WITH PRODUCT LAUNCH
CYTOGEN ACQUIRES RIGHTS TO PAIN RELIEF AGENT FOR BONE CANCER
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
CYTOGEN AND CYTORAD ANNOUNCE AGREEMENT TO MERGE
CYTOGEN COMPLETES EXCHANGE OFFER FOR CYTORAD UNITS
CYTOGEN CORPORATION ANNOUNCES UPDATE ON FIRST QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
Progenics and Cytogen Announce Progress on Vaccine and Antibody Therapies for Prostate Cancer.
CytRx forms prostate cancer alliance with Cytogen and Progenics.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters